Abstract:OBJECTIVE To evaluate the dosing regimens of levofloxacin. METHODS The drug concentrations in serum and urine were assayed by HPLC method and the pharmacokinetic parameters were calculated after intravenous infusion of a single dose of 200 mg, 300 mg and 500 mg levofloxacin to healthy volunteers. The in vitro activity MIC of levofloxacin against 823 clinical isolates were determined and compared with other antimicrobial agents. Based on the above results, the PK/PD parameters C(max)/MIC and AUC/MIC were calculated and the dosing regimens of levofloxacin were proposed for infections caused by different pathogens. RESULTS The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg. The in vitro pharmacodynamic study showed that levofloxacin was highly active against Hemolytic streptococcus and Moraxella catarrhalis. It was active against Streptococcus pneumoniae (including penicillin nonsusceptible strains), Hemophilus influenzae, methicillin-sensitive Staphylococcus aureus (MSSA), Klebsiella pneumoniae and Stenotrophomonas maltophilia. Levofloxacin also had good activity against Pseudomonas aeruginosa and K.pneumoniae. However, most of isolates of enterococcal spp. were resistant to levofloxacin. Above 50% of Escherichia coli isolates were resistant to levofloxacin. Based on the results of PK/PD parameters, the adequate dosing regimens of levofloxacin should be once daily 200 mg once daily of levofloxacin was expected to be effective for the treatment of infections caused by M. catarrhalis. The regimen of 300 mg once daily could be effective for the treatment of infections caused by Hemolytic streptococcus. 500 mg once daily of levofloxacin was expected to be effective for the treatment of respiratory tract infections caused by S. pneumoniae or H. influenzae. For treatment of respiratory tract infections and urinary tract infections caused by levofloxacin-susceptible organisms including K. pneumoniae, E. coli, P. aeruginosa, and S.maltophilia, 500 mg once daily of levofloxacin was needed to obtain good clinical efficacy. But PK/PD parameters predicted that 500 mg daily of levofloxacin was not effective for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Enterococci. CONCLUSION The proposed dosing regimens of levofloxacin based on PK/PD concepts are expected to provide good efficacy in clinical practice.

Pharmacokinetic and pharmacodynamic analysis of flomoxef against the clinical isolates of strains

In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China

A 10 Year Surveillance for Antimicrobial Susceptibility of Escherichia Coli and Klebsiella Pneumoniae in Community- and Hospital-Associated Intra-Abdominal Infections in China

Antimicrobial Resistance Surveillance of Flomoxef in China

Antibacterial Effect Evaluation of Moxalactam Against Extended-Spectrum Β-Lactamase-producing Escherichia Coli and Klebsiella Pneumoniae with in Vitro Pharmacokinetics/pharmacodynamics Simulation

In vitro Activity of Cefmetazole and Flomoxef among Extended-Spectrum Beta-Lactamase producing Enterobacterales

Sitafloxacin Pharmacokinetics/pharmacodynamics Against Multidrug-Resistant Bacteria in a Dynamic Urinary Tract Infection in Vitro Model.

In Vivo Bioluminescent Monitoring of Therapeutic Efficacy and Pharmacodynamic Target Assessment of Antofloxacin Against Escherichia Coli in a Neutropenic Murine Thigh Infection Model.

In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae.

[Study of Pharmacokinetics/pharmacodynamics of Levofloxacin].

Pharmacokinetic and Pharmacodynamic Analysis of the Oxacephem Antibiotic Flomoxef against Extended-Spectrum β-Lactamase-Producing Enterobacterales from Dogs

Clinical outcomes of flomoxef versus cefmetazole in hospitalized patients with urinary tract infections: Combined retrospective analyses of two real-world databases and in vitro data.

Pharmacokinetics/pharmacodynamics of Antofloxacin Hydrochloride in a Neutropenic Murine Thigh Model Ofstaphylococcus Aureusinfection

In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin Against Klebsiella Pneumoniae in a Neutropenic Murine Lung Infection Model.

Concentration-resistance relationship and PK/PD evaluation of danofloxacin against emergence of resistant Pasteurella multocida in an in vitro dynamic model

Comparison of Mutant Prevention Concentrations of Fluoroquinolones Against ESBL-Positive and ESBL-Negative Klebsiella pneumoniae Isolates from Orthopedic Patients

Simulating Moxalactam Dosage for Extended-Spectrum Β-Lactamase-producing Enterobacteriaceae Using Blood Antimicrobial Surveillance Network Data.

Pharmacodynamic Target Attainment of Seven Antimicrobials Against Gram-negative Bacteria Collected from China in 2003 and 2004.

A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia

The In-Vitro Sustained Effects of Antofloxacin Hydrochloride against Staphylococcus Aureus and Escherichia Coli

The intracellular concentrations of fluoroquinolones determined the antibiotic resistance response of Escherichia coli